Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension

Journal of the American College of Cardiology

Volumn 34, Issue 4, 1999, Pages 1188-1192

  Nagaya, Noritoshi ^a   Uematsu, Masaaki ^b   Okano, Yoshiaki ^c   Satoh, Toru ^a   Kyotani, Shingo ^a   Sakamaki, Fumio ^a   Nakanishi, Norifumi ^a   Miyatake, Kunio ^a   Kunieda, Takeyoshi ^d  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CALCIUM ANTAGONIST; DIGITALIS; DIURETIC AGENT; NITRATE; PROSTACYCLIN DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DIARRHEA; FEMALE; FLUSHING; HEADACHE; HEART OUTPUT; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; VASODILATOR AGENTS;

EID: 3042686863     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00312-5     Document Type: Article

References (25)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension : a national prospective study. Ann Intern Med 1987;107:216-23.
2. Rubin LJ, Peter RH. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 1980;302:69-73.
3. Rubin LJ, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med 1983;99: 433-8.
4. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence of long-term reduction in pulmonary arterial pressure and regression in right ventricular hypertrophy. Circulation 1987;76:135-41.
5. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Resistry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30.
6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
7. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982;306:557-64.
8. Glanville AR, Burke CM, Theodore J, Robin ED. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 1987;91:675-81.
9. Pasque MK, Trulock EP, Kaiser LD, Cooper JD. Single lung transplantation for pulmonary hypertension: three month hemodynamic follow-up. Circulation 1991;84:2275-9.
10. Higenbottam TW, Wheeldon D, Wells FC, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
11. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91.
12. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
13. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
14. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
15. Sim AK, McCraw AP, Cleland ME, et al. Effects of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittel-Forsch 1985;35:1816-8.
16. Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium 2: absorption, distribution and excretion after single administration of beraprost sodium in rat. Xenobio Metabol Dispos 1989;4:101-16.
17. Murata T, Murai T, Kanai T, et al. General pharmacology of beraprost sodium, second communication: effects on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimittel-Forsch 1989;39:867-76.
18. Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365.
19. Selzer A, Sudrann RB. Reliability of the determination of cardiac output in man by means of the Fick principle. Circ Res 1958;6:485-90.
20. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994;89:1733-44.
21. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
22. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
23. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
24. Yuki H, Sato S, Arisaka Y, et al. Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats. Tohoku J Exp Med 1994;173:371-5.
25. Ichida F, Uese K, Tsubata S, et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997;80:662-4.